Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.
Sreeni Chittoor, MD, FACP
Advertisement
Articles by Sreeni Chittoor, MD, FACP
Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Chittoor on Guidelines for Liquid Biopsies in NSCLCPublished: January 15th 2020 | Updated:
Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLCPublished: January 24th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5